About The Company

Creative Clinical Concepts (CCC) was organized in 2002. Our mission is to promote and provide cost-effective utilization of clinical laboratory testing to assist in the prediction of risk, prevention, diagnosis, prognosis, and management of clinical disease states. Early identification of individuals at increased risk of clinical events and optimization of traditional and complementary and alternative therapeutic and preventative measures will enhance the quality of human life.

CCC was founded on a strong background of experience in clinical laboratory testing and research, with particular emphasis in the area of hemostasis and laboratory medicine.

Chronic Inflammation Test

A test to measure 11-dehydrothromboxane B2 (major metabolite of thromboxane A2) in urine was developed together with Corgenix, Inc., a Denver-based in-vitro diagnostic manufacturing company, and Cayman Chemical Company, an Ann Arbor, Michigan manufacturer of biochemical research products. In 2007, the FDA cleared the test under the trade name AspirinWorks® for the detection of aspirin’s effects in apparently healthy individuals. In 2016, CCC, in collaboration with AMS Laboratory in Wichita, Kansas, conducted an IRB-approved laboratory validation study to establish a reference range for the Chronic Inflammation Test as an inflammatory marker test. Inflammation was ruled out in the reference range population by utilizing hs-CRP, fibrinogen, and WBC testing together with personal history in apparently healthy individuals.